Testing people for gene changes linked to cancer risk
Checks people for KRAS and other microRNA binding gene changes in an observational study.
Key facts
- Who runs it
- MiraKind
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Registry title
- Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
- Status
- Recruiting
- People taking part
- 15,000 people, planned
- Started
- Sept 2014
- Expected to end
- Sept 2035
- Type of study
- Observational, 4 groups
- Treatments tested
- KRAS-variant and microRNA binding site mutation testing
- Record updated
- 23 January 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with a personal or family history of cancer, or a personal history of endometriosis or autoimmunity. Participants may have the KRAS-variant or other microRNA binding site mutations.
- Age
- 18 years and older
- Sex
- All sexes can join.
- Biomarker or test result
- Testing for the KRAS-variant and other microRNA binding site mutations.
Main reasons for not taking part
- Younger than 18
- Non-English speaking and unable to understand and sign the consent
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Personal or family history of cancer
- Personal history of endometriosis, or autoimmunity
Who cannot take part
- Younger than 18
- Non-english speaking and unable to understand and sign the consent
Where in United States
- MiraKindLos Angeles, United StatesContact: Joanne Weidhaas, MDPhDTaking people
About the trial
What the trial wants to find out
The investigators will recruit and enroll individuals that may have the KRAS-variant or other microRNA binding site mutations to join registry studies. The investigators will allow individuals to obtain their results through a physician at the completion of the studies. The investigators current focus is cancer and autoimmunity.
The 4 groups in the trial
- Family Registry
For individuals identified with the KRAS-variant. Patients will be prospectively followed to determine the impact of lifestyle on disease risk.
Treatment: KRAS-variant and microRNA binding site mutation testing
- Double primary breast cancer
Women with multiple primary breast cancer will be tested for the KRAS-variant and compared between those with this mutation and those without.
Treatment: KRAS-variant and microRNA binding site mutation testing
- Autoimmunity
We have shown that the KRAS-variant and other members of this genetic class of mutations associate with altered immunity, leading to immunosuppression as well as autoimmunity.
Treatment: KRAS-variant and microRNA binding site mutation testing
- Cancer patients receiving certain treatments
We have found that microRNA binding site mutations are predictive biomarkers of outcomes from cancer therapy, including response and toxicity. We will enroll patients to further study and validate these findings.
Treatment: KRAS-variant and microRNA binding site mutation testing
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Clinical Validation of the Role of microRNA Binding Site Mutations in Cancer Risk, Prevention and Treatment
- Plain-language title
- Testing people for gene changes linked to cancer riskGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 23 January 2025